Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial

Greenwich Lifesciences

22/01/2026 11:26

** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 14% to $25.53 premarket

** Co says U.S FDA cleared first batch of GP2 vials for use in a late‑stage breast cancer study

** GP2 is an experimental immunotherapy aimed at preventing breast cancer from returning after standard treatment

** GLSI says the approval reduces manufacturing‑related risks ahead of a potential U.S. marketing application

** Trial is enrolling at 40 U.S. sites and may expand to as many as 150 globally; more than 1,000 patients screened so far, co says

** Co says early data shows an estimated 80% reduction in cancer recurrence, though findings are preliminary

** Shares up ~87% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))